Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation ExpenseEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetWages, Salaries and Other
Ratios

Protalix BioTherapeutics (PLX) Receivables - Net (2016 - 2025)

Protalix BioTherapeutics has reported Receivables - Net over the past 16 years, most recently at $8.8 million for Q4 2025.

  • Quarterly results put Receivables - Net at $8.8 million for Q4 2025, up 203.88% from a year ago — trailing twelve months through Dec 2025 was $8.8 million (up 203.88% YoY), and the annual figure for FY2025 was $8.8 million, up 203.88%.
  • Receivables - Net for Q4 2025 was $8.8 million at Protalix BioTherapeutics, down from $14.4 million in the prior quarter.
  • Over the last five years, Receivables - Net for PLX hit a ceiling of $14.4 million in Q3 2025 and a floor of $1.3 million in Q1 2023.
  • Median Receivables - Net over the past 5 years was $4.6 million (2021), compared with a mean of $5.7 million.
  • Biggest five-year swings in Receivables - Net: crashed 77.93% in 2023 and later skyrocketed 557.18% in 2025.
  • Protalix BioTherapeutics' Receivables - Net stood at $3.4 million in 2021, then skyrocketed by 33.24% to $4.6 million in 2022, then rose by 14.96% to $5.3 million in 2023, then crashed by 44.82% to $2.9 million in 2024, then soared by 203.88% to $8.8 million in 2025.
  • The last three reported values for Receivables - Net were $8.8 million (Q4 2025), $14.4 million (Q3 2025), and $9.4 million (Q2 2025) per Business Quant data.